Showing results (181-190 of 243) with videos related to
Sort By:
Pageof 25
Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry databaseSatoshi Ikeda, Takashi Ogura, Etsuo Miyaoka, et al.Frontiers in Pharmacology|May 27, 2024
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patientsTakeru Kashiwada, Ryotaro Takano, Fumihiko Ando, et al.JTO Clinical and Research Reports|November 8, 2021
CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary FibrosisAya Fukuizumi, Rintaro Noro, Masahiro Seike, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFREisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, et al.Oxford Medical Case Reports|October 27, 2018
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravisTakehiro Tozuka, Teppei Sugano, Rintaro Noro, et al.Thoracic Cancer|July 14, 2020
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastasesTakehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, et al.Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatmentTakehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, et al.Thoracic Cancer|February 26, 2020
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancerTeppei Sugano, Masahiro Seike, Yoshinobu Saito, et al.BMC Cancer|March 14, 2020
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitorsTakehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, et al.Respiratory Medicine Case Reports|February 7, 2019
Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestationsJunichi Aoyama, Hiroki Hayashi, Chika Yajima, et al.Pageof 25